Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > Articles by: Murtaza Awan

Author: Murtaza Awan

Drug Product Recall: Water For Injection Manufactured By M/S. Amros Pharmaceuticals, Karachi.

Murtaza Awan Recall Alerts February 10, 2022February 22, 2022QA & LT

Adulterated And Substandard Water For Injection Manufactured By M/S. Amros Pharmaceuticals, Karachi

Word FileDownload

Drug Product Recall: Pantoloon Tablets (Batch # 5602) By M/S. Rock Pharmaceutical Laboratories (Pvt.) Ltd. Risalpur

Murtaza Awan Recall Alerts February 8, 2022February 22, 2022QA & LT

Substandard Pantoloon Tablets Manufactured By M/S. Rock Pharmaceutical Laboratories (Pvt.) Ltd. Risalpur.

PDF FileDownload

Drug Product Recall: M/S. Pfizer Pakistan Limited, Karachi issues nation wide voluntary recall of Meronem 500mg Injection (Batch #4B20E273) and Meronem 1gm Injection (Batch # 4A20E25)

Murtaza Awan Recall Alerts February 8, 2022February 22, 2022QA & LT

PDF FileDownload

Drug Product Recalls: Cozol Suspension (Batch # E206) By M/S. Alkemy Pharmaceutical Laboratories (Pvt.) Ltd. Hyderabad

Murtaza Awan Recall Alerts February 8, 2022February 23, 2022QA & LT

Substandard Cozol Suspension Manufactured By M/S. Alkemy Pharmaceutical Laboratories (Pvt.) Ltd. Hyderabad

PDF FileDownload

Tender Documents For Purchase Of Pharmacy Refrigerators For DRAP

Murtaza Awan Tenders January 13, 2022January 13, 2022Other

Purchase Of Pharmacy Refrigerators For DRAP

PDF FIle Download

The Therapeutic Goods (Federal Inspectors, Laboratories and Federal Government Analysts) Rules, 2022 for comments

Murtaza Awan Drugs January 5, 2022March 1, 2022QA & LT

The Therapeutic Goods (Federal Inspectors, Laboratories and Federal Government Analysts) Rules, 2022

Word File Download

Draft Guidelines On Good Pharmacovigilance Practices For Registration Holders for view Comments to be Submitted to National PV Center DRAP till 15th January, 2022

Murtaza Awan General December 29, 2021January 6, 2022Pharmacy Services

Guidelines On Good Pharmacovigilance Practices For Registration Holders

PDF File Download

User Guide For Online Import / Export Applications Software

Murtaza Awan Drugs, General December 28, 2021January 6, 2022QA & LT

User Guide For Online Import / Export Applications Software.

PDF FileDownload

Drug Product Recall: Dextrose 25% Infusion (Batch# A042C21) by M/s Otsuka Pakistan Ltd, Hub, Baluchistan

Murtaza Awan Recall Alerts December 28, 2021February 22, 2022QA & LT

CDL has declared Dextrose Infusion 25% (Batch # A042C21) as substandard, Manufactured By M/S. Otsuka Pakistan Ltd., Hub.

PDF FileDownload

Pre-Submission Screening Checklist for Biological Registration Dossier

Murtaza Awan Drugs December 22, 2021December 27, 2021Guidelines

Application shall be received for detailed evaluation if all the below mentioned documents are submitted.

PDF FileDownload
  • ← Previous

Archives

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • February 2019
  • January 2019
  • December 2018
  • October 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • February 2018
  • November 2017
  • October 2017
  • July 2017
  • June 2017
  • May 2017
  • March 2017
  • November 2016
  • June 2016
  • March 2016
  • May 2014
  • March 2014
  • January 2014
  • October 2013
  • August 2013
  • April 2013
  • October 2012
  • July 2012
  • March 2012
  • February 2002

Meta

  • Log in

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem